Whether as primary tumors or metastases, brain tumors remain stubbornly intractable to the progress that has occurred in many other tumor types. As Igor Vivanco, who is a senior lecturer in the Institute of Pharmaceutical Science at King’s College London, noted in his talk at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) meeting in Paris this week, the last win in glioblastoma was the addition of temozolomide to the radiotherapy standard of care in 2005. And temozolomide’s benefit is measured in months, not years. Read More
Autoantibodies are typically not good news. But a group of researchers from Bellinzona, Switzerland, have observed that the presence of autoantibodies against chemokines, a special class of cytokines, is associated with mild disease and less risk of developing long COVID. “Our hypothesis was that antibodies to chemokines, if they existed, would also be associated with a negative outcome of the disease. But, what we found, in fact, was the exact opposite of what we were predicting,” Davide Robbiani, director of the Institute for Research in Biomedicine, told BioWorld. Read More
Novelmed Therapeutics Inc. has announced that NM-3086, the lead clinical asset in its properdin-associated alternative pathway (AP) program... Read More
Aldosterone acts as a mediator of hypertension, heart failure and kidney disease, and aldosterone synthase inhibitors (ASIs) have emerged as... Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed naphthyridine derivatives acting as ATR kinase inhibitors reported to be useful... Read More
Current antithrombotic therapies for the prevention and management of cardiovascular disorders such as thrombosis, myocardial infarction (MI) or stroke present an associated risk of bleeding. The essential events leading to the formation of hemostatic clots are platelet activation and fibrin formation. When activated, the prostacyclin (IP) receptor prevents platelet aggregation in arteries and veins after injury. Read More
Jacobio Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer. Read More
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified sulfonamide derivatives acting as histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from the University of Illinois Urbana-Champaign have published data from a study designed to assess the role of serine-arginine-rich splicing factor 1 (SRSF1) in hepatocyte function and survival. Read More
To date, there is a lack of consensus in anal cancer screening. DNA methylation markers zing finger protein 582 (ZNF582) and achaete-scute homolog 1 (ASCL1) have been associated with anal intraepithelial neoplasia (AIN3) and anal carcinoma risk in people with HIV infection. Read More
University of Pisa has divulged metformin prodrugs reported to be useful for the treatment of cancer, type 2 diabetes and cardiovascular disorders. Read More
Researchers from the University of British Columbia presented data from a study that aimed to define the role of nuclear receptor subfamily 1 group H member 3 (NR1H3) in the pathophysiological mechanisms that drive increased risk, severity and progression in multiple sclerosis (MS). Read More
Albert-Ludwigs-Universitaet Freiburg has described methyltransferase N6AMT1 (KMT9) inhibitors reported to be useful for the treatment of cancer. Read More
